|
|
GLA-LSQ |
|
Vaxjo ID |
162 |
|
Vaccine Adjuvant Name |
GLA-LSQ |
|
Adjuvant VO ID |
VO_0005421
|
|
Description |
liposome formulation containing the Toll-like receptor (TLR)-4 agonist containing GLA that induces a mixed Th1/Th2 reponse |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
GLA and SQ-21 |
|
Storage |
2-8C |
|
Preparation |
liposome formulation |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=63]
Radtke et al., 2017: Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, Howard RF, Sher A, Germain RN, Duffy P. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Scientific reports. 2017; 7; 40312. [PubMed: 28091576].
|
|
